Applied Filters
Fed Circuit invalidates Purdue oxycodone patent
The Federal Circuit has upheld a finding of the US Patent and Trademark Office, which rendered a Purdue Pharma oxycodone patent ineligible.
Hologics and Grifols agree $14m Enzo settlement
Enzo Life Sciences has entered into a settlement and licensing agreement with pharmaceutical companies Hologic and Grifols, ending a patent dispute between the parties.
Canadian generics plan could deter big pharma: report
Plans by Canada’s government to improve access to generic drugs could deter pharmaceutical companies from releasing brand medicine in the country, according to an internal government report.
SCOTUS refuses to hear tribal immunity suit
The US Supreme Court has declined to hear a closely-watched case on tribal immunity involving pharmaceutical company Allergan and the Saint Regis Mohawk Tribe, a Native American tribe.
Fresenius files IPR against Amgen
Fresenius Kabi has submitted a petition for inter partes review of US patent number 9,856,287, a patent owned by Amgen.
AG weighs in on Bayer patent case
An advocate general has advised the Court of Justice of the European Union on damages in a case between Bayer and pharmaceutical companies Richter and Exeltis.
EU complains to WTO over Turkey’s pharma measures
The European Union has asked the World Trade Organization to initiate dispute consultations with Turkey over requirements imposed by the country on pharmaceutical products.
China, Canada and US labs collaborate over neurological disorder therapies
Chinese companies have entered into a research agreement with scientists in the US and Canada to develop a therapy for neurological disorders by using the natural power of the immune system.
Duane Morris hires Winston & Strawn lawyer
Duane Morris & Selvam has strengthened its IP practice with the addition of John Alison from Winston & Strawn.
Athena asks for rehearing on invalidated neurological disorder patent
Athena Diagnostics has asked the US Federal Circuit to revisit its decision earlier this year, which found four claims in one of its patents to be invalid.
